AstraZeneca’s injectable antibody therapy AZD7442 has succeeded in cutting risk of people with COVID-19 progressing to severe illness or death, but has fallen short of the efficacy achieved in similar studies of rival treatments from Regeneron, Eli Lilly and Vir/GSK.
Results from its Phase III TACKLE study found that AZD7442 (tixagevimab and cilgavimab) given by intramuscular injection, cut the risk...






